AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04393948 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Phase 1
Description: Dose Level 1 - 100 cGy irradiation to a single (right-sided) lung using 6 MV photons delivered using a clinical linear accelerator
Study NCT04393948 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Phase 1
Description: Dose Level 2 - 100 cGy irradiation to both lungs using 6 MV photons delivered using a clinical linear accelerator
Study NCT04393948 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Phase 2
Description: Arm A - No irradiation
Study NCT04393948 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Phase 2
Description: Arm B - 100 cGy irradiation to a single (right-sided) lung using 6 MV photons delivered using a clinical linear accelerator
Study NCT04393948 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Phase 2
Description: Arm C - 100 cGy irradiation to both lungs using 6 MV photons delivered using a clinical linear accelerator
Study NCT02177357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Study NCT02177357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03770455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab 10mg/kg every 2 weeks (Q2W) + 2nd generation ADT
Study NCT03770455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2nd generation ADT (abiraterone or enzalutamide)
Description: 2nd generation ADT (abiraterone or enzalutamide)
Study NCT01143012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group eczema education session
Description: Subjects in the intervention group will participate in a group education visit to discuss topics such as subjects' general understanding and knowledge of eczema and its treatment.
Study NCT01143012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group will not attend the group eczema education session.
Study NCT02602327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tas-102
Description: Oral nucleoside antitumor agent consisting of α,α,α-trifluorothymidine (FTD) and 5-chloro-6-(2-iminopyrrolidin-1-yl) methyl-2,4 (1H,3H)-pyrimidinedione hydro chloride (TPI) at a molar ratio of 1:0.5.
Study NCT02602327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIR-Sphere
Description: 20-60mm resin microspheres containing Yttrium-90 (90Y, Y90) radioisotope
Study NCT03676829 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arterial Embolization of the Shoulder
Description: Arterial Embolization of the Shoulder (AES) is a new procedure that is being used to reduce pain and improve range of motion (ROM) caused by adhesive capsulitis. Embolization is a procedure where physicians intentionally block the blood vessels to specific areas of the body to prevent blood flow to that region. By doing this, the decrease in blood flow will decrease the size of the area of interest. In this case, the goal is to decrease the size of inflammatory tissue around the shoulder, resulting in improvement of pain, stiffness and from adhesive capsulitis.
Study NCT03137004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 50mg/m2 in 60 min on day 1 and repeated every 14 days.
Study NCT03137004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1 was administered orally at 40 mg/m2 twice daily on days 1-7 of each cycle. Patients with a body surface area of less than 1.25 m2 received 80 mg S-1 daily, those with a body surface area of 1.25 m2 or more but less than 1.5 m2 received 100 mg S-1 daily, and those with a body surface area of 1.5 m2 or more received 120 mg S-1 daily.
Study NCT02929004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrasens
Description: Transcutaneous vibrations are used. This device allows vibrations from 25 to 150 Hz with an amplitude of 1 mm. In our study the frequency used is 50 Hz.
Study NCT02546570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: See arm/group descriptions for dosage amount and procedure.
Study NCT02546570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: See arm/group descriptions for dosage amount and procedure.
Study NCT03630900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequential O2 Culture
Description: We investigate the effect of sequential O2 levels on human embryo culture after Intracytoplasmic sperm injection (ICSI)
Study NCT02863042 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repair Deltoid Tendon
Study NCT02863042 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ankle Fracture Without Deltoid Tendon Repair
Description: Standard of care
Study NCT04168086 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound
Description: Low intensity focused ultrasound is sound energy stimulation at a low intensity of 1-30 W/cm2
Study NCT04168086 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The investigators will simulate focused ultrasound stimulation similar to the experimental groups but without stimulation.
Study NCT00787293 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant
Description: Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein, anterior interventricular vein.
Study NCT00873002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: panobinostat
Description: Dose escalation: 7.5 mg/m2 day 1 and day 8 of 21 days cycle 10 mg/m2 day 1 and day 8 of 21 days cycle 15 mg/m2 day 1 and day 8 of 21 days cycle 20 mg/m2 day 1 and day 8 of 21 days cycle 30 mg/m2 day 1 and day 8 of 21 days cycle
Study NCT00873002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sorafenib tosylate
Description: 400 mg PO BID
Study NCT02594501 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COBRA PzF
Study NCT02594501 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug Eluting Stent
Study NCT01424852 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotics in infant milk formula
Description: Probiotic infgant milk formula administered during the forst year of life
Study NCT01424852 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics in infant milk formula
Description: Probiotic infgant milk formula administered during the forst year of life
Study NCT02899871 — intervention group
Intervention type: OTHER
Intervention: diagnosis of joint
Description: The diagnosis of joint pain will be established by a rheumatologist and completed:~* If necessary, by a clinically guided radiological assessment (plain x-rays, joint ultrasound, bone and joint MRI).~* serum assays of the anti-TNF administered, as well as screening for associated antibodies.
Study NCT03723447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Liposomal bupivacaine will be given during the bilateral laparoscopic-guided TAP block given to each patient intraoperatively.
Study NCT03723447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine/epinephrine/dexamethasone
Description: Bupivacaine/epinephrine/dexamethasone will be given during the bilateral laparoscopic-guided TAP block administered to each patient intraoperatively.
Study NCT02619422 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intensive cardiac rehabilitation program in less time
Description: 2 weeks, 5 days a week, and reinforcement sessions at 3, 6 and 9 months
Study NCT01606878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT02026570 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internal Focus of Attention
Description: Providing instructions for the user to manipulate their residual limb in space during standing and walking tasks.
Study NCT00592683 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: tablet, start at 2mg and increase/decrease each week, taken daily for 12 weeks
Study NCT00592683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aripiprazole
Description: tablet, start at 2mg and increase/decrease each week, taken daily for 12 weeks
Study NCT00592683 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fish oil
Description: 1600mg (4 capsules) daily for 12 weeks
Study NCT00592683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03804983 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control-IQ with MyTDI
Description: Participants will use their own insulin parameters during the first 5 days of the study. After randomization at the ski admission, the participants insulin parameters will be modified using the MyTDI calculations. Additionally, parameters will be reduced 20% during the ski admission to adjust for the increased activity.
Study NCT00139113 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis A vaccine
Description: 2 doses of inactivated hepatitis A vaccine manufactured by GSK in licensed pediatric formulation of 720 EL. U. per dose given on 3 different schedules: aged 6 and 12 months, 12 and 18 months, and 15 and 21 months. Within each group, subjects were randomized to achieve a relatively equal number of children born to anti-HAV positive and anti-HAV negative mothers.
Study NCT02317510 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined anesthesia
Description: Combined Spinal Epidural Anesthesia for laparoscopic cholecystectomy
Study NCT02317510 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia
Description: General anesthesia for laparoscopic cholecystectomy
Study NCT03456115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical nasal dilator
Description: Participants will be asked to trial 5 different mechanical nasal dilators. 4 of which are commercially available and one of which is the investigational device being studied for feasibility. The 4 commercially available nasal dilators include Breathe Right, Max Air, Sleep Right, Nozovent. The fifth device is the study team's investigational device dubbed the Schnozzle.
Study NCT01392833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: intravenous methylprednisolone 1 g for three consecutive days at the beginning of months 1, 3 and 5
Study NCT01392833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: intravenous methylprednisolone 1 g for three consecutive days at the beginning of months 1, 3 and 5
Study NCT01392833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azathioprine
Description: azathioprine 1.5 mg/kg/day for six months followed by azathioprine 50 mg/day for a further six months.
Study NCT01392833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: prednisone 0.5 mg/kg every other day followed by prednisone 0.2 mg/kg every other day for a further six months.
Study NCT01392833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: prednisone 0.5 mg/kg every other day followed by prednisone 0.2 mg/kg every other day for a further six months.
Study NCT02216565 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Hospitalization in specialized neuro-vascular unit
Study NCT02216565 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Alteplase if patient is eligible
Description: Alteplase intravenous thrombolysis performed if patient is eligible (if not contraindicated)
Study NCT02216565 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Supportive care
Description: Drugs, procedures and techniques aimed at preventing/managing complications or aggravation of the patient's neurological condition
Study NCT00139113 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hepatitis A vaccine
Description: 2 doses of inactivated hepatitis A vaccine manufactured by GSK in licensed pediatric formulation of 720 EL. U. per dose given on 3 different schedules: aged 6 and 12 months, 12 and 18 months, and 15 and 21 months. Within each group, subjects were randomized to achieve a relatively equal number of children born to anti-HAV positive and anti-HAV negative mothers.
Study NCT02216565 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endovascular treatment
Description: Recanalization treatment (thrombectomy / intraarterial thrombolysis)
Study NCT01814657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine hydrochloride (HCl) 1% solution
Description: Comparison of paracervical block using Lidocaine versus Normal Saline placebo in patients undergoing oocyte retrieval during IVF.
Study NCT01814657 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Normal Saline%
Description: Sterile normal saline used as placebo for lidocaine hydrochloride (HCl)1% solution
Study NCT01122927 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg) pill taken orally once per day
Study NCT03480321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol 100 mg
Description: One immediately-release tablet (Cilostazol 100 mg) at 08:00 and another at 20:00, twice daily oral dose (total daily dose of 200 mg)
Study NCT03480321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMR 150 mg
Description: Two extended-release tablets (PMR 150 mg) at 08:00, single oral dose (total daily dose of 300 mg)
Study NCT03480321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMR 200 mg
Description: Two extended-release tablets (PMR 200 mg/tablet) at 08:00, single oral dose (total daily dose of 400 mg)
Study NCT02132663 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control: Marketed routine infant formula
Study NCT02132663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: An investigational infant formula containing an alternate source of DHA
Study NCT02281591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093
Description: Tablets containing 900 mg
Study NCT02281591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-licarbazepine
Description: capsules containing 225 mg
Study NCT02281591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-licarbazepine
Description: capsules containing 225 mg
Study NCT03141671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH
Description: -blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
Study NCT03141671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: -blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
Study NCT03141671 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Salvage radiation
Description: Radiation
Study NCT03141671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone
Description: -blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
Study NCT02026570 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: External Focus of Attention
Description: Providing instructions for the user to manipulate their prosthetic foot in space during standing and walking tasks.
Study NCT04689438 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: gingival crevicular fluid
Description: GCF samples were collected in the morning hours 24-48 hours after clinical periodontal measurement.
Study NCT01887093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walking
Description: Participants in both walking groups were requested to walk at the speed of 2.5 miles/h for 30 min/day or more on at least 5 days/week for a period of 12 weeks.One group was asked to walk in the morning and the other group was asked to walk in the evening.
Study NCT03615508 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 10% phenylephrine
Description: 10% phenylephrine is a drug that can be used to dilate patient's eyes at their yearly eye examination. All enrolled subjects will receive this drug for their eye dilation.
Study NCT03473548 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable sleep monitor
Description: Type III at home portable monitor obtaining greater than or equal to 6 hours of data adequate for polysomnography analysis
Study NCT03473548 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-laboratory Polysomnography
Description: Polysomnography testing will determine the sleep stages, apnea hypopnea index (AHI), blood saturation oxygen nadir (SPO2 nadir), and average blood oxygen saturation. A McGill Oximetry Score will also be calculated for the in-laboratory PSG.
Study NCT04093063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Micro-stellated Icosahedron
Description: A portable, inexpensive microsurgery training model that requires the following materials for completion. a stereoscopic dissecting microscope, two jeweler style forceps, a pair of curved-tip micro scissors , 1 meter of monofilament nylon thread, 0.5 meter of polyimide microtubule material , one 15 cm metal ruler, a scalpel blade (#15), and double-sided tape. For a microsurgically-naive subject, a total of 20 hours are required to complete this model.
Study NCT02192840 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary angioplasty with stent implantation
Description: Coronary angioplasty in bifurcation lesion with drug-eluting stent implantation: BiOSS or regular DES (rDES)
Study NCT02192840 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary angioplasty with stent implantation
Description: Coronary angioplasty in bifurcation lesion with drug-eluting stent implantation: BiOSS or regular DES (rDES)
Study NCT02380690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Coach Assignment
Description: Veterans will be assigned a peer coach to meet with for 6 months to discuss pain self-management.
Study NCT01585584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir
Description: All patients will receive a 4-week lead-in with Peginterferon and Ribavirin therapy, followed by 24 weeks of Pegetron 1.5microg/kg + weight-based ribavirin + boceprevir 800mg tid. HCV RNA (Cobas TaqMan) will be measured at baseline and at treatment weeks 4, 6,8,12,16,20,24 and 28, and post-treatment weeks 12 and 24 (to obtain SVR-12 and SVR-24 results).
Study NCT00727532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400mg by mouth twice daily for 28 consecutive days
Study NCT00829933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DU-176b tablets
Description: DU-176b tablets taken once daily for up to 12 weeks
Study NCT00829933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin potassium tablets
Description: Warfarin potassium tablets taken once daily for up to 12 weeks
Study NCT03551262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OTSC
Description: Positioning of OTSC in bleeding peptic ulcer
Study NCT03551262 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TTS clip
Description: Positioning of TTS clip in bleeding peptic ulcer
Study NCT01844167 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Noxipoint Therapy (NT)
Description: • For severe chronic neck pain patients, cervical braces are recommended within the first 2-3 days of each treatment session. The patient has to avoid using the treated tissues/muscles during the Rest Period: Similar to all other cells, the muscle cell healing or regeneration takes time. Patients are instructed not to use the newly recovered muscle/tissue during the Rest Period, which is about three days if they are forty or younger, plus about one extra day for every 10 additional years of age. If the patient has extensive injured muscles, take two more days of rest. Ice packs may be used during or soon after the session to prevent Delayed Onset of Muscle Soreness (DOMS) from the TENS stimulation.
Study NCT01844167 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physical therapy(PT)
Description: •Placebo effect consideration: TENS is included in both arms to obfuscate the process. Using TENS in the PT arm serves both as a sham-therapy-equivalent to what is used in the NT arm to neutralize placebo bias, and as a meaningful therapeutic remedy. The subject is thus blinded. Placebo effect consideration: TENS is included in both arms to obfuscate the process. Using TENS in the PT arm serves both as a sham-therapy-equivalent to what is used in the NT arm to neutralize placebo bias, and as a meaningful therapeutic remedy. The subject is thus blinded.
Study NCT00004190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00004190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Study NCT00306111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Single dose (6mg) one day after chemotherapy
Study NCT01804829 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Civacir® 10%
Description: The active ingredient is Human Immunoglobulin G (IgG) which is a normal constituent purified from human source plasma containing a diversity of antibodies targeting the Hepatitis C Virus.
Study NCT03961477 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interferential therapy
Description: Exercise therapy